Drugs / 18F-2-fluoro-2-deoxy-D-glucose
18F-2-fluoro-2-deoxy-D-glucose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05828238 | Jan 2023 → Jan 2024 | breast cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-2-fluoro-2-deoxy-D-glucose | “comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)” NCT05828238 ↗ |
| Known as | 18F-FDG | “Drug: [18F]-FDG” NCT05828238 ↗ |
| Known as | FDG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05828238 ↗ |